Dysregulation of BCL-2 proteins has been demonstrated in many hematological malignancies, including the hallmark translocation t (14; 18) involving BCL-2 in follicular lymphoma, but also in other non-Hodgkin lymphomas, multiple myeloma, chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [2,3]. Here, BCL2 is linked to plasma cell myeloma.